echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cinda BioCD47/PD-L1 B2specific Antibody Phase I Clinical Study completed the first patient administration in China.

    Cinda BioCD47/PD-L1 B2specific Antibody Phase I Clinical Study completed the first patient administration in China.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Guide: IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both PD-1/PD-L1 and CD47/SIRP-alpha pathways.
    Cinda Biopharmaceuticals has just announced that its potential lying phase I clinical study of anti-CD47/PD-L1 bispecific antibodies (research code: IBI322) has completed the first patient administration in China.
    the study (CIBI322A101) is a phase Ia/Ib clinical study conducted in China to evaluate IBI322 treatment of subjects with advanced malignancies, the main purpose of which was to assess the safety, tolerance and antiactive tumors of IBI322 bispecific antibody therapy in subjects with advanced malignancies that failed standard treatment.
    IBI322 is an anti-CD47/PD-L1 bispecific antibody that blocks both The PD-1/PD-L1 and CD47/SIRP-alpha pathways.
    preclinical studies show that IBI322 can effectively block the binding of SIRP-alpha and CD47, induce macrophages to perform a phagocytopharycal effect on tumor cells expressing CD47, the ability is comparable to anti-CD47 monoantiphoresis;
    also due to the presence of PD-L1, IBI322 selectivebinding to tumor cells is more capable than anti-CD47 monogenic, thereby reducing the binding to CD47 on the surface of red blood cells, reducing the possibility of associated toxicity.
    , IBI322 has better anti-tumor activity and greater safety. Professor Wang Jie, Director of Oncology Medicine at the Chinese Medical Hospital of
    , said: "Although immunocheckpoint inhibitors have shown welcome results in the treatment of a wide range of tumors, they still face many new challenges.
    With the increasing popularity of immunocheckpoint inhibitors in tumor therapy, a number of patients who are resistant to them have appeared clinically. At the same time
    , the efficacy of immunocheckpoint inhibitors needs to be further improved.
    , therefore, the development of the next generation of dual-specific tumor immunodrugs has important clinical significance.
    CD47 is one of the most promising and potential targets in tumor immunotherapy, combined with the innovative technology of bispecific antibodies, the clinical results of IBI322 are very much expected. "Bispecific antibodies target effect cells directly against tumor cells, enhancing cytotoxicity and improving the selectivity and functional affinity of antibodies," said Dr. Hui Zhou, Vice President, Medical Science and Strategic Oncology, Cinda Biopharmaceutical Group,
    preliminary results show that IBI322 has better in vivo efficacy, tumor concentration distribution, and higher safety than single-specific anti-CD47 antibodies.
    bispecific antibodies can create lower drug costs for patients than two monoclonal antibody drugs combined with drug therapy.
    , the development of anti-CD47/PD-L1 bispecific antibodies will provide patients with a new, comprehensive, effective and cost-effective treatment.
    We hope iBI322 will benefit more patients.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.